44 Top Revenue Generating Cannabis Stocks Ranked as of March 15th – New Cannabis Ventures

The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This data-driven, fact-based tracker will continually update based on new financial filings so that readers can stay up to date. Companies must file with the SEC or SEDAR to be considered for inclusion. Please note that we expect to raise the minimum quarterly revenue in April to US$5 million.

44 companies currently qualify for inclusion, with 27 filing in U.S dollars and 17 in the Canadian currency. Since our last report in mid-February, we have added Alcanna (TSX: CLIQ) (OTC: LQSIF), as we had suggested would be the case. We expect to add several companies in the coming months, including TILT Holdings (CSE: TILT) (OTC: TILTF), which announced very strong January pro forma revenue and is likely to qualify for its Q4, which should be reported in March or April.

So far in March,  Acreage Holdings (CSE: ACRG.U) (OTC: ACRGF), CV Sciences (OTC: CVSI), Innovative Industrial Properties (NYSE: IIPR) and Terra Tech (OTC: TRTC) have reported. Acreage holdings reported sales of $10.5 million, up 90% from the prior quarter and 344% from a year ago. The company also shared a pro forma revenue of $22.9 million, which takes into account revenue from managed entities. CV Sciences revenue growth slowed slightly during its Q4, which the company attributed to some temporary regulatory push-back in a few states. The company’s revenue of $14.2 million grew 96% from a year ago and 4% from the prior quarter. Innovative Industrial Properties continues to see strong growth in its financial metrics, which included revenue growth of 110% from a year ago and 22% from the prior quarter to $4.8 million. Finally, Terra Tech continued to see pressure on its California operations, with cannabis-related revenue in Nevada and

Read More Here...

Leave a Comment

Please Rate This Content*

Your email address will not be published. Required fields are marked *